---
title: CDMOs offering Viral Vector Manufacturing with mRNA
path: /explore/viral-vector-manufacturing/mrna
companies_count: 13
---

# CDMOs offering Viral Vector Manufacturing with mRNA

13 published CDMOs match Viral Vector Manufacturing and mRNA.

Locations in this set include United States, United Kingdom, China, Denmark, Spain, and Belgium.

Capabilities that show up most often in this set: CMC Analytical Development, mRNA Manufacturing, Process Development, Cell-Line Development, and Cell Therapy Manufacturing.

## Matching companies

- [4basebio](/companies/4basebio)
  - 4basebio manufactures high-quality synthetic DNA and RNA using proprietary cell-free amplification technology, supporting mRNA vaccines, viral vectors, gene editing, and cell/gene therapies from research through GMP-grade clinical production.
- [AGC Biologics](/companies/agcbio)
  - Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
- [Aldevron](/companies/aldevron)
  - Aldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.
- [Artis BioSolutions](/companies/artis-biosolutions)
  - Integrated CDMO platform combining proprietary enzymatic synthetic DNA production with advanced therapy development and GMP manufacturing for mRNA, gene editing, viral vectors, cell therapies, and vaccines.
- [Asimov](/companies/asimov)
  - Asimov provides cell line development, upstream process development, and viral vector manufacturing services powered by proprietary synthetic biology platforms (CHO Edge, LV Edge, AAV Edge, RNA Edge) that deliver high-titer, stable cell lines and production systems for biologics, cell therapies, and gene therapies.
- [Creative Biogene](/companies/creative-biogene)
  - Creative Biogene provides viral vector manufacturing, cell line development, and RNA therapeutic platforms including AAV, lentivirus, adenovirus production, circular RNA synthesis, and lipid nanoparticle formulation for gene therapy and vaccine applications.
- [ElevateBio](/companies/elevate)
  - Advanced therapies CDMO providing discovery, process development, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA, and gene editing programs from preclinical through commercial scale.
- [Patheon (Thermo Fisher Pharma Services)](/companies/patheon)
  - Patheon is a trusted global contract development and manufacturing organization (CDMO) partner owned by Thermo Fisher Scientific, offering 360° integrated solutions from early-stage R&D through clinical supply and commercial manufacturing.
- [Pharmaron](/companies/pharmaron)
  - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- [Porton Advanced](/companies/porton-advanced)
  - End-to-end ATMP CDMO provider offering cell engineering, lentiviral vectors, mRNA/LNP, plasmid development, and GMP manufacturing from preclinical through commercialization with 24 IND approvals across NMPA, FDA, and MedSafe.
- [Symbiosis Pharmaceutical Services](/companies/symbiosis-pharma)
  - UK-based fill-finish CDMO offering rapid access to GMP aseptic manufacturing for clinical and commercial injectable drug products across mAbs, ATMPs, ADCs, RNA, peptides, vaccines, and small molecules.
- [Syngene International](/companies/syngeneintl)
  - Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- [eXmoor Pharma](/companies/exmoorpharma)
  - Integrated cell and gene therapy CDMO with 20+ years of consultancy expertise, offering end-to-end CMC support from early-phase strategy through GMP manufacturing across viral vectors, autologous/allogeneic cell therapies, and RNA technologies.